2017 Fiscal Year Final Research Report
Development of innovative therapy combining molecularly targeted drugs and immunotherapy
| Project/Area Number |
26461419
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | ダサチニブ / 免疫チェックポイント阻害剤 / NK細胞 / サイトメガロウイルス |
|---|
| Outline of Final Research Achievements |
We found expansion of memory-like NK cells in peripheral blood of chronic myeloid leukemia and Ph-positive acute lymphoblastic leukemia patients treated with dasatinib, and revealed that cytomegalovirus reactivation plays an important role in lymphocytosis observed in these patients. Furthermore, increases in PD-1-expressing CD56-negative NK cells were noted in these patients. Cytotoxic activity of these PD-1-expressing NK cells were enhanced by PD-1 blockade with nivolumab. In a mouse model using a colon cancer cell line, CT26, combination therapy with dasatinib and anti-PD-L1 antibody did not show any synergistic effect.
|
| Free Research Field |
免疫学
|
